AI assistant
GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2007
Jul 26, 2007
65022_rns_2007-07-26_466cee2c-5129-451c-939f-67594edba328.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [562 x 65] intentionally omitted <==
==> picture [562 x 66] intentionally omitted <==
ASX ANNOUNCEMENT July 27[th] , 2007
Genetic Technologies Achieves Operating Cash Milestone
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that, for the first time in the Company’s history, GTG has generated positive net cash flows from operating activities in respect of the financial year ended June 30, 2007.
The total cash receipts from operations and interest for the 2007 year exceeded $15 million, with consolidated net cash inflows from operations of approximately $2.6 million. These figures compare favourably to those for the previous financial year which delivered total cash receipts of $8.5 million and a net cash deficit from operations of almost $6.0 million.
This significant turnaround was driven by a 70% increase in revenue from licensing activities and a 23% increase in revenue from the Company’s genetic testing operations, whilst operating cash costs incurred during the year were materially lower than for the previous year.
It should be noted that the following figures have been prepared in accordance with accounting standards applicable in Australia, have been rounded to the nearest $10,000 and are yet to be audited and may therefore be subject to change.
| nd may therefore be subject to change. | |||
|---|---|---|---|
| 2007 | 2006 | Change from prior year | |
| (unaudited) | (actual) | ||
| Revenue from licensing activities | $11,340,000 | $6,685,248 | Increase of 70% |
| Revenue from genetic testing activities | $3,120,000 | $2,550,221 | Increase of 23% |
| Net cash flows from operations | $2,620,000 | $(5,957,322) | Increase of $8.6 million |
| Cash reserves | $13,780,000 | $11,885,247 | Increase of 16% |
The Company believes that the positive results for the 2007 financial year just ended validate the strategies now being pursued by GTG and provide a sound platform for further growth and expansion in the 2008 financial year.
Further detailed financial information will be contained in the upcoming ASX Appendix 4C for the quarter ended 30 June 2007, and the ASX Appendix 4E which will be released in late August 2007.
FOR FURTHER INFORMATION PLEASE CONTACT
Thomas G. Howitt Dr. Mervyn Jacobson Chief Financial Officer Chief Executive Officer Genetic Technologies Limited Genetic Technologies Limited Phone: +61 3 9415 1135 Phone: +61 3 9415 1135
Genetic Technologies Limited • Website : www.gtg.com.au • Email : [email protected] ABN 17 009 212 328 Registered Office • 60-70 Hanover Street Fitzroy VIC 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone 61 3 9415 1135 • Fax 61 3 9417 2987